Magazine Article | August 1, 2022

Venture Philanthropy Launches Biotech From Within

Source: Life Science Leader

By Matthew Pillar, Editor, Bioprocess Online

At the time I hosted Ben Yerxa, Ph.D., as a guest on episode 94 of the Business of Biotech podcast, he was serving as CEO of Foundation Fighting Blindness, the Retinal Degeneration Fund, and Opus Genetics — three distinct but interwoven organizations with one common goal fighting blindness. In late June, though, he handed off his leadership duties at Foundation Funding Blindness and Retinal Degeneration Fund management to focus on leading Opus Genetics, a biopharma with three preclinical programs addressing gene mutations that cause severe vision loss at an early age (i.e., Leber congenital amaurosis).

access the Magazine Article!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Life Science Leader? Subscribe today.

Subscribe to Life Science Leader X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Life Science Leader